Cocrystal Pharma (FRA:8CC) Growth Rank: 0 (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8CC Cocrystal Pharma Inc FRA:8CC
31 GF Score
Price €0.95
GF Value €2.43
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cocrystal Pharma Growth Rank?

Cocrystal Pharma has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Cocrystal Pharma Growth Rank Related Terms

FRA:8CC
31GF Score
Cocrystal Pharma Inc FRA:8CC
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cocrystal Pharma (FRA:8CC) Overvalued in 2026?

Based on GuruFocus' analysis, Cocrystal Pharma stock appears to be undervalued. The current stock price of €0.95 is trading 61.1% below its estimated GF Value™ of €2.43. GuruFocus considers Cocrystal Pharma to be Possible Value Trap.

Key valuation signals for FRA:8CC:

  • Growth Rank: 0
  • GF Value™: €2.43 vs. price of €0.95 (61.1% below fair value)
  • GF Score™: 31/100 with 4 warning signs

No single metric tells the full story. See the FRA:8CC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cocrystal Pharma Business Description

Other Exchanges COCP:USA
Address 19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
31GF Score

Get the complete analysis for FRA:8CC

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.95
Price
€2.43
GF Value